mismatch repair proteins, was BRAF wild type at V600E, were under 60 years of age at diagnosis, and demonstrated no promoter region methylation for MLH1 in tumor DNA. A validation cohort of 44 colorectal cancers from mismatch repair germline mutation carriers from the Australasian Colorectal Cancer Family Registry (ACCFR) were sequenced for the most common truncating mutation hotspots (X117 and X659). RNF43 mutations were found in 9 of 24 (37.5%) Lynch syndrome colorectal cancers. The majority of mutations were frameshift deletions in the G659 G7 repeat tract (29%); 2 cancers (2/24, 8%) from the one patient harbored frameshift mutations at codon R117 (C6 repeat tract) within exon 3. In the ACCFR validation cohort, RNF43 hotspot mutations were identified in 19/44 (43.2%) of samples, which was not significantly different to the initial series. The proportion of mutant RNF43 in Lynch syndrome related colorectal cancers is significantly lower than the previously reported mutation rate found in sporadic MSI colorectal cancers. These findings identify further genetic differences between sporadic and hereditary colorectal cancers. This may be because Lynch Syndrome cancers commonly arise in colorectal adenomas already bearing the APC mutation, whereas sporadic microsatellite unstable colorectal cancers arise from serrated polyps typically lacking APC mutation, decreasing the selection pressure on other WNT signaling related loci in Lynch syndrome.
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Abstract The WNT signaling pathway is commonly altered during colorectal cancer development. The E3 ubiquitin ligase, RNF43, negatively regulates the WNT signal through increased ubiquitination and subsequent degradation of the Frizzled receptor. RNF43 has recently been reported to harbor frequent truncating frameshift mutations in sporadic microsatellite unstable (MSI) colorectal cancers. This study assesses the relative frequency of RNF43 mutations in hereditary colorectal cancers arising in the setting of Lynch syndrome. The entire coding region of RNF43 was Sanger sequenced in 24 colorectal cancers from 23 patients who either (i) carried a germline mutation in one of the DNA mismatch repair genes (MLH1, MSH6, MSH2, PMS2), or (ii) showed immunohistochemical loss of expression of one or more of the DNA
Introduction
The WNT signaling pathway is frequently altered during colorectal carcinogenesis [1] . The E3 ubiquitin ligase, RNF43, acts as a negative regulator of the WNT pathway by inducing ubiquitin-mediated endocytosis of cell surface Frizzled receptors [2] . Recently, RNF43 has been proposed as a key mutational target of microsatellite unstable (MSI) sporadic colorectal cancers [1, 3, 4] .
Microsatellite instability refers to the high frequency of mutations within microsatellite (repetitive) regions of the genome [5] , which develops as a result of impairment of a DNA mismatch repair gene [6] . Mutations driven by MSI occur most frequently in non-coding genomic regions but may also target coding repeat tracts in key tumor suppressor genes. Such mutations in key tumor suppressor genes including TGFRBII [7] contribute to tumor progression.
Lynch syndrome is the most common cause of hereditary colorectal cancer resulting from germline mutations in one of the DNA mismatch repair genes, predominantly in MLH1 or MSH2, but also in the binding partners MSH6 and PMS2 [8] .
Recent studies have shown that microsatellite instability arising in a sporadic setting is significantly associated with somatic mutation of the RNF43 gene [3, 4, 9] . RNF43 is a ubiquitin ligase that dampens the WNT signal. It achieves this through ubiquitination, inducing the endocytosis and subsequent degradation of the Frizzled receptor on the cell surface [2] . Inhibition of RNF43 has been implicated in the increase in expression of Frizzled receptors on the cell membrane and resultant increased WNT signal. In sporadic MSI colorectal cancer, frameshift events have been shown to occur in repeat tracks of RNF43, primarily a single nucleotide deletion in the G7 repeat tract occurring in codon 659 within exon 9 [3] . We have previously identified a high rate of G7 repeat tract mutations (87%) in sporadic MSI colorectal cancers [3] compared with only 4% in microsatellite stable colorectal cancers [3] .
In this study, we assessed the frequency of somatic mutational events within RNF43 in two cohorts of Lynch syndrome colorectal cancers and compared this with previously reported RNF43 somatic mutation frequency from sporadic MSI colorectal cancers.
Methods

Patient samples
The discovery cohort was comprised of 24 Lynch syndrome related colorectal cancer samples collected from patients at the time of surgical resection at the Royal Brisbane and Women's Hospital, Australia. Tumor samples were snap-frozen in liquid nitrogen and DNA was extracted using salt precipitation [10] 
Sample selection
Cancers were included in this study if they met the following criteria: (i) carriers of a germline mutation in one of the DNA mismatch repair genes (MLH1, MSH6, MSH2, PMS2), or (ii) showed immunohistochemical loss of expression of one or more of the four DNA mismatch repair proteins, was BRAF wild type at V600E, patient age <60 years at colorectal cancer diagnosis, demonstrated no promoter region methylation for MLH1 in tumor DNA, and were determined to have MSI. This was assessed using the National Cancer Institute's 5 marker panel [5] where MSI was classified if at least one mononucleotide and at least one other marker was positive [11] .
Sequence analysis
Tumor DNA was amplified by PCR (See Table 1 for primer sequences). The primers were designed using Primer3 BLAST in conjunction with sequence data obtained from the CHIP SNPPER [12] online tool. Separate primers were designed for the ACCFR validation cohort to flank only the exon 3 and 9 hotspot (Table 1) . PCR conditions are available on request. The PCR products were then treated with the ExoSapIT (Affymetrix, OH, USA) reagent as per the manufacturer's protocol and sequenced on an ABI3100 Capillary sequencer (Applied Biosystems, USA) ( Table 1) .
Software and statistical analysis
Statistical analysis was performed using GraphPad Prism 7 with a student's t test used for categorical data analysis. P values of <0.05 were considered statistically significant.
Results
Clinical and molecular features of Cohort
The discovery cohort (Brisbane cohort) consisted of 10 female and 14 male colorectal cancer-affected patients.
The mean age of colorectal cancer diagnosis for patients was 48.40 ± 11.52 years. DNA mismatch repair immunohistochemistry results were available for 14 tumors. Loss of immunohistochemical staining was most frequently observed for the MLH1 (6/14, 43%) and MSH2 (5/14, 36%) proteins. Fifteen samples had a documented germline mismatch repair mutation. No tumors had a BRAF V600E mutation, whilst all tumors were microsatellite unstable ( Table 2 ). The ACCFR validation cohort was comprised of colorectal cancers from 18 female and 26 male participants confirmed to carry a germline DNA mismatch repair gene mutation. The mean age of colorectal cancer diagnosis was 50.1 ± 12.26 years. DNA mismatch repair immunohistochemistry results were available for all patients in the cohort. The most common germline defects were in the MLH1 (18/44, 41%), and MSH2 (17/44, 39%) genes (Table 3 ). All patients in the validation cohort were wildtype at BRAF V600E .
Lynch syndrome colorectal cancers harbor moderate rates of RNF43 frameshift mutations
In the discovery cohort, we identified 9 (37.5%) RNF43 somatic mutations, all of which were frameshift events. Seven mutations (7/24, 29.1%) occurred at the hotspot G659 within exon 9 involving frameshift deletions of the G7 repeat tract. (Table 2 ; Fig. 1 ). The remaining two mutations (8.3%) occurred at R117 within exon 3 involving a frameshift within a C6 repeat tract. This occurred in two synchronous cancers from the same patient. In order to rule out a germline mutation we sequenced matched normal mucosal DNA, where we did not observe the R117 frameshift mutation.No sample contained more than one mutation. We sought to confirm the mutation rate of these two hotspot truncating events at X659 and X117 in a validation cohort (ACCFR Cohort) comprised of 44 colorectal cancers with confirmed germline mismatch repair gene mutations. Overall, RNF43 was mutated in 19/44 samples (43.2%) where X659 hotspot mutations were identified in 16 tumors (16/44, 36.3%), and X117 mutations in 3 samples (3/44, 6.8%) ( Table 3) . No instances of concurrent X117 and X659 mutations in either cohort were observed. We found no statistically significant relationship between clinical data and mutation status of RNF43. Similarly, we found no evidence of an association between the specific mismatch repair gene deficiency and RNF43 mutational frequency.
Lynch syndrome colorectal cancers have significantly lower RNF43 mutation rates than sporadic colorectal cancers
We compared results from this study to previously obtained RNF43 mutational data from sporadic colorectal cancer patients [3, 9] . Bond et al. reported RNF43 somatic mutations in 47/54 (87.0%) sporadic MSI colorectal cancers; 43 (80%) of mutations identified were the X659 hotspot mutation and 6 (11%) were the X117 mutation [3] , while Yan et al. reported truncating RNF43 mutations in 17/20 (85%) sporadic MSI colorectal cancers in the initial cohort, and 30/39 (77%) sporadic MSI colorectal cancers in the TCGA validation cohort. (Fig. 2) [9] . We compared the rate of RNF43 hotspot truncating mutations in our Lynch syndrome colorectal cancer cohorts to both Yan et al. -3′   2  GAG AAA GGA AGG GCC AAA AA  GAG AAA GGA AGG GCC AAA AA  3  CCA GCA TCC TGA AGT GAC AA  GGA AAC ATG GGG ACA AGA GA  4  TTA GAC CCA GTG ACC CCT TG  TCA GCG TCA TTA CCC CAG AT  5  CAT CAC TGA GGA TCG AGC TG  TGT AGG TGA GGC CCA AAG AC  6  TAA TCC CAC TTG CAG GTT CC  ACA GAC GCT GGG GTA TTT TG  7  TGA GTG ACT GGG AAC GGA GT  CAG GAC ACA TGG GAA ACA GA  8  TGA TGC CAA AGC TCA TAC CA  GTG GCA GTT CTG CTT TCT CC  9A  CCA GAG CAC AGG CAG CTT AG  GGG TGC TGT GAG GTG GAT TG  9B  CTG GTC CCT TCC TGC CAT C  GGT CAC ACT AGG CTG CAT GT  9C  ACT CTG TGG TCA ACT GCA CG  CAC TGT GGG TTA GAG AGC CG  9D CCT [14] , typically via downstream pathogenic CNNTB1 mutations, and to a lesser extent, APC mutation [15] [16] [17] . Loss of APC mutations occur in large proportions of conventional adenomas [14, 17] , which are the precursor lesions to malignant Lynch syndrome colorectal cancers. In contrast, sporadic MSI colorectal cancer typically arise from the serrated polyps, which harbor high proportions of oncogenic BRAF mutations, namely BRAF V600E and lower frequencies of APC mutations. Native APC regulates the WNT signaling pathway through degradation of β-catenin by forming a co-degradation complex with GSK3 and AXIN [18] . Pathogenic APC mutations prevent the complex from degrading β-catenin efficiently which then accumulates in the cell nucleus. Loss of APC as seen in Lynch syndrome cancers could reduce deleterious selection pressures at the RNF43 locus and this is further supported by the mutational exclusivity shown between RNF43 and APC [4] . Yan and colleagues noted in organoid studies that induction of the X659 frameshift mutation resulted in a phenotype of decreased dependence on R-spondin-1 and increased WNT dependence [9] . This is in line with the previous prediction of the deleterious nature of RNF43 mutations noted by Giannakins et al. [4] . The current study adds further evidence supporting this hypothesis. The selective nature of the mutations seen between the hereditary MSI and sporadic MSI cohorts indicates the high likelihood of a biological advantage to RNF43 mutations in sporadic MSI colorectal cancer.
Inhibition of the WNT signaling pathway has proved challenging in cancer with mutated APC, however upstream inhibition of porcupine has shown some promise in a subsection of colorectal cancers.
LGK974 is a small molecular inhibitor that targets Porcupine and results in a decreased WNT ligand secretion.
LGK974 inhibits Porcupine and as a result reduces the level of WNT ligand secretion [19] . Reduction of WNT ligand secretion reduces Frizzled-WNT binding capacity and therefore results in a decrease in canonical WNT signaling. Inhibition of WNT ligand secretion can increase differentiation and decrease proliferation in WNT dependent cell lines [19] . Porcupine inhibitors have been shown to be exclusively effective against RNF43 mutant cell lines [3, 20] . Cancers with deficient RNF43 are unable to ubiquitinate and subsequently degrade surface Frizzled receptors thereby allowing the WNT pathway to continuously signal. As the majority of sporadic MSI colorectal cancers harbor the mutant RNF43 genotype required for sensitivity, LGK974 may be an appropriate targeted therapy for this cancer type and is currently undergoing stage I/II safety and efficacy studies [21, 22] . However, we propose that hereditary Lynch syndrome MSI colorectal cancers should not be assumed to be sensitive to LGK974 or other porcupine inhibitors based solely on their MSI status, given they display a significantly lower rate of RNF43 mutations than sporadic MSI colorectal carcinomas.
Here, we report that RNF43 is less frequently mutated in hereditary versus sporadic MSI colorectal cancers. It is possible that differences in mutation preference is a result of selective pressures acting differentially on loci in the setting of sporadic versus Lynch syndrome colorectal cancer. Further, our study indicated that hereditary MSI colorectal cancers face significantly less selective pressure for RNF43 inactivation, possibly due to pre-existing downstream mutation of other WNT pathway members, as previously reported in the literature [17] . Lastly, Porcupine inhibition may play a reduced role in Lynch syndrome colorectal cancer treatment as they have a lower mutation rate and hence are less likely to be sensitive to this therapeutic approach. Combined mutation rate (%) at hotspots X117 and X659 from Lynch syndrome cohorts and previously reported sporadic microsatellite unstable colorectal cancers [3, 9] . Asterisk Indicates significance below 0.05 versus all sporadic cohorts
